All posts

DRCT stock is a buy, Roth says

Roth MKM analyst Darren Aftahi thinks Direct Digital Holdings (Direct Digital Holdings Stock Quote, Chart, News, Analysts, Financials Nasdaq:DRCT) has more to give.

In a research update to clients November 27, Aftahi maintained his “Buy” rating on DRCT but raised his price target on the stock from $9.50 to $12.50. The analyst explained the reasoning behind the move.

“We believe there may be more of a “margin upside” story to DRCT than previously thought,” he said.  “While the topline growth is unquestioned and superior to peers, we believe the market may not appreciate a potential longer-term improvement in adj. EBITDA margins. Currently, DRCT uses BidSwitch to connect it to various partners in the programmatic ecosystem. However, our recent conversations with DRCT’s management suggest that it could look to strike more direct deals over time. This would mitigate the need for a middleman and improve margins as a result. We have spoken with numerous players in the DSP and SSP space, who suggest direct deals could improve passthrough margins by an average of 200-500 bps. In the case of DRCT, we believe this would be pure margin dropping straight to the bottom line.”

The analyst thinks DRCT will post EBITDA of $14.7-million on revenue of $180.2-million in fiscal 2023. He expect those numbers will improve to EBITDA of $19.9-million on a topline of $240.6-million the following year.

“We are not adjusting any numbers at this time but do highlight that at the midpoint of this range (350 bps), this would imply an $8.4M benefit to adj. EBITDA (on our 2024 estimate), or a 42% benefit,” the analyst concluded. “We believe the company endeavors to shift traffic from BidSwitch (the underlying infrastructure that normalizes the connections between different programmatic technology platforms; most commonly DSPs and SSPs), however, this goal is more long-term in nature. Any upside to margins would make an already 40% 2-year projected CAGR in adj. EBITDA (ROTH MKM estimates) even better. With that in mind, we have re-evaluated the multiple we apply to DRCT shares. Peers trade at a mean ~9.1x EV/’24E EBITDA currently. With well above average growth, and the potential for an improved adj. EBITDA story longer-term, we apply a ~10x multiple to our ~$20M ’24 estimate, which implies a fair value of $12.50 per share, which is our new PT.”

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: drct
Nick Waddell

Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.

Recent Posts

Antibe Therapeutics has more upside still, Paradigm says

The stock has been on a roll, but Paradigm Capital analyst Scott McAuley thinks there is still money to be… [Read More]

12 hours ago

CRDO earns price target raise at Roth

Following the company's most recent results, Roth MKM analyst Suji Desilva has raised his price target on Credo Technology Group… [Read More]

12 hours ago

CargoJet’s Q4 was solid, Beacon says

Its fourth quarter results are in the books and Beacon Securities analyst Ahmad Shaath remains bullish on Cargojet (Cargojet Stock… [Read More]

1 day ago

Pet Valu is a buy, Beacon Securities says

Beacon Securities analyst Doug Cooper likes what he sees from Pet Valu Holdings (Pet Valu Holdings Stock Quote, Chart, News,… [Read More]

1 day ago

HEALWELL AI is undervalued, Clarus says

Clarus Securities analyst George Ulybyshev likes what he sees from HEALWELL AI (HEALWELL AI Stock Quote, Chart, News, Analysts, Financials… [Read More]

2 days ago

SYZ stock is a buy, Echelon says

Ahead of the company's Q4 results, Echelon Capital Markets analyst Amr Ezzat thinks there is still money to be made… [Read More]

2 days ago